re: Ann: Major Milestone - 78.6% Success in B... just as a mater...

re: Ann: Major Milestone - 78.6% Success in B... just as a mater of interest to this sector. HeartWare’s submission for CE Mark was based on data from the first 25 patients to have been
implanted in the Company’s international clinical trial. Of these 25 patients, 23 patients (92 percent)
survived to 180 days or to heart transplantation, the primary endpoint of the trial. A total of 50
patients were enrolled in the trial. Within this broader group, the survival rate has remained above 90
percent.
“It has been a great pleasure to be involved in the HeartWare trial,” said Dr. Georg Wieselthaler of
the Medical University of Vienna, the clinical trial’s principal investigator. “The Vienna team was the
first to implant the HeartWare device and our enthusiasm for this pump has grown during the trial.
This miniature centrifugal pump has distinct design features that give rise to important clinical
advantages. I expect the HeartWare® System to play an important role in the future management of
heart failure.”
Dr. Martin Strueber, principal investigator at Hannover Medical School, the highest enrolling center